Blueprint Medicines Announces European Commission Approval For AYVAKYT
Blueprint Medicines Corporation?(BPMC) announced the European Commission has approved AYVAKYT for the?treatment of adult patients with indolent systemic mastocytosis with moderate to severe symptoms inadequately controlled on symptomatic treatment.